Supply Issues Becton Dickinson Safety Peripheral Intravenous Cannulas FSP5004 and FSP5005 (ICN 3515)

Change:

• The supplier Becton Dickinson has informed us of a supply issue with its safety peripheral intravenous cannulas.
• There are two products affected:
  • FSP5004 − Safety Peripheral Intravenous Cannula Ported With Wings Grey 16G x 45mm PUR
  • FSP5005 − Safety Peripheral Intravenous Cannula Ported With Wings Orange 14G x 45mm PUR.
• The supply issue is due to increased demand and lead times.
• Due to this ongoing supply issue, FSP5004 is now being threshold managed as they are subject to Protect Demand Management.

Impact:

• FSP5005 is subject to intermittent supply.
• FSP5004 is available to order through NHS Supply Chain. However, trusts are allocated a maximum daily quantity or “threshold” to ensure fair supply of available stock across the NHS.
• Potential indirect alternative products are available to order through our online catalogue.
• See our Downloads ▼ section to access the product listing for further information on the affected product codes and potential alternatives and for a full list of product codes subject to Protect Demand Management.
• The supply issue is anticipated to be resolved by 16 November 2026.

Next Steps:

• Customers are advised to log into our website to view the product listing for further information on the affected product codes and potential alternatives.
• The continuing supply issue is being monitored in conjunction with the supplier, and we will continue to review the stock situation to minimise further disruption and update this ICN with the latest information as it becomes available.
• However, as this is currently a disrupted market and supply is subject to rapid change, the alternatives offered may also be experiencing temporary supply issues and therefore, customers may need to consider clinically reviewing all additional alternatives provided.
• If you have any further questions, please contact your local NHS Supply Chain Customer Services Advisor.

Please note that due to the clinical nature of these alternative products, we advise you to consult your own clinical experts to ensure suitability for your organisations use of these products.